FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement